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Abstract
Background: Early diagnosis and continuous monitoring are necessary for an efficient management of cervical
cancers (CC). Liquid biopsy, such as detecting circulating tumor DNA (ctDNA) from blood, is a simple, non-invasive
method for testing and monitoring cancer markers. However, tumor-specific alterations in ctDNA have not been
extensively investigated or compared to other circulating biomarkers in the diagnosis and monitoring of the CC.
Therfore, Next-generation sequencing (NGS) analysis with blood samples can be a new approach for highly
accurate diagnosis and monitoring of the CC.
Method: Using a bioinformatics approach, we designed a panel of 24 genes associated with CC to detect and
characterize patterns of somatic single-nucleotide variations, indels, and copy number variations. Our NGS CC panel
covers most of the genes in The Cancer Genome Atlas (TCGA) as well as additional cancer driver and tumor
suppressor genes. We profiled the variants in ctDNA from 24 CC patients who were being treated with systemic
chemotherapy and local radiotherapy at the Jeonbuk National University Hospital, Korea.
Result: Eighteen out of 24 genes in our NGS CC panel had mutations across the 24 CC patients, including somatic
alterations of mutated genes (ZFHX3–83%, KMT2C-79%, KMT2D-79%, NSD1–67%, ATM-38% and RNF213–27%). We
demonstrated that the RNF213 mutation could be used potentially used as a monitoring marker for response to
chemo- and radiotherapy.
Conclusion: We developed our NGS CC panel and demostrated that our NGS panel can be useful for the diagnosis
and monitoring of the CC, since the panel detected the common somatic variations in CC patients and we
observed how these genetic variations change according to the treatment pattern of the patient.
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Background
Cervical cancer (CC) is the third most frequently di-
agnosed cancer and the fourth most common cause
of cancer-related death among women worldwide,
particularly in developing countries [1]. Although the
development of a screening method for human papil-
lomavirus (HPV)-based diagnosis for CC and HPV
vaccination have lowered the incidence and death
rate, this cancer still remains among the most com-
mon causes of cancer-related death in women [2].
High-risk human papillomavirus (HR-HPV), which is
difficult to eradicate by the host immune system, in-
fects the epithelial layer of the cutaneous and muco-
sal surfaces [3, 4]. The mechanism of HR-HPV
infection is an important carcinogenic factor that in-
creases the risk of CC development over time. It has
been reported that 15–30% of patients with early-
stage CC experience recurrences after surgical oper-
ation, and half of those who previously had recurrent
cancer show a higher risk of another recurrent can-
cer within 3 years after primary treatment. Thus, it
is recommended that patients visit clinics for check-
ups every 3–4 months for the first 2 years, and every
6–12 months for the next 3–5 years after initial treat-
ment to monitor the recurrence of CC [5]. During a
check-up for cancer recurrence, cervical cytology,
measurement of squamous cell carcinoma antigen
and CA-125 in the blood, and medical imaging tech-
niques such as computed tomography, magnetic res-
onance imaging, and positron emission spectroscopy
are performed. However, the cervical cytology and
the blood tests are limited by their low sensitivity
and specificity. Medical imaging techniques can be
employed to improve the detection of cancer recurrence,
but they are costly and involve radiation exposure. Recent
liquid biopsy studies showed that cell-free DNA
(cfDNA), which originates from the apoptosis and
necrosis of normal and tumor cells may be valuable
for monitoring tumor behaviors and treatment re-
sponses [6–8]. The detection of HPV16 and HPV18
DNA or alterations in the cfDNA of patients with
CC patients is used as biomarkers for recurrence
monitoring [9–11].
For these reasons, we built a custom NGS panel
consisting of 24 genes related to gynecological can-
cers. In this study, we assessed the clinical utility of
analyzing gene mutations in CC patients who have a
medical history of chemotherapy and radiotherapy,
profiling the genetic variations in cfDNA from 24 pa-
tients. As a result, we were able to obtain the muta-
tional variations in ctDNA and observe their patterns
over time, which can be used to detect the phases of
CC, monitor the tumor status, and predict therapeutic
responses.
Methods
Samples and clinical data
A total of 24 CC patients were enrolled in a prospective
cohort at the Jeonbuk National University Hospital. All
subjects provided an informed consent to participate in
the study, and all clinical specimens were collected with
approval from the institutional review board (IRB No.
CUH2017–04–018-001) and ethics committee of Jeon-
buk National University Hospital. Total of 7 ml of whole
peripheral blood was collected into EDTA tubes from
each patient approximately 1 week before chemotherapy.
Genetic variations were analyzed using our NGS CC
panel. For each patient, mutations were characterized
from both cfDNA, plasma, and peripheral blood mono-
nuclear cells (PBMCs).
Sample preparation
PBMCs were isolated from 7ml of whole blood by dens-
ity gradient centrifugation in Ficoll-Paque™ PLUS (GE
Healthcare, Little Chalfont, UK). We extracted cfDNA
from isolated plasma using the QIAamp Circulating
Nucleic Acid Kit (Qiagen, Hilden, Germany) according
to the manufacturer’s instructions. The extracted DNA
was quantified using a Qubit 3.0 fluorometer (Invitro-
gen, Carlsbad, CA, USA). We analyzed the quality of
cfDNA using the 2100 Bioanalyzer (Agilent Technolo-
gies, Santa Clara, CA, USA) to detect genomic DNA
contamination.
Next-generation-sequencing
A total of 2265 amplicons were designed in two primer
pools to capture the targeted regions. Amplicon size was
designed to be 125–140 base pairs (bp), and the total
number of bases covered by the amplicons was 169.34
kb. A total of 10 ng of cfDNA and PBMC-derived DNA
was used for library construction. Library preparation
was performed using an Ion Ampliseq Library Kit 2.0
(Thermo Fisher Scientific, Waltham, MA, USA) accord-
ing to the manufacturer’s instructions. We used the Ion
Express Barcode Adaptors Kit (Thermo Fisher Scientific)
for sample multiplexing, and libraries were purified
using the Agencourt AMPure XP reagent (Beckman
Coulter, Brea, CA, USA). Libraries were quantified using
the Qubit 3.0 fluorometer and 2100 Bioanalyzer. Tem-
plate preparation of the libraries was performed using
the Ion Chef Instrument (Thermo Fisher Scientific) with
an Ion 540 Chef Kit (Thermo Fisher Scientific). Multi-
plexed templates were subjected to sequencing on the
Ion S5 XL system (Thermo Fisher Scientific). PBMCs
were evaluated to analyze somatic mutations and ex-
clude germline mutations. Our panel can detect 0.1%
tumor mutated cfDNA to normal cfDNA (range of read
depths from 1000x to 3902x with a median read depth
of 1554x). However, given the percentage of mutated
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tumor present in cfDNA, we set cut-off value of vari-
ation as 1%.
Variant analysis
The human genome sequence hg19 was used as a refer-
ence for variant calling. Sequence and data analyses were
performed using Torrent Suite software (5.8.0). Sequen-
cing coverage analysis was performed using coverage
Analysis (5.8.0.1) plugins, and VCF files were generated
using the variantCaller (5.8.0.19) plugins. Annotations of
the variants were obtained using Ion Reporter (5.10.2.0)
software. To filter out the potential sequencing back-
ground noise, we excluded common Korean single-
nucleotide variations, which are from KoVariome
(http://variome.net). whole genome sequence database
of 50 healthy unrelated Korean individuals [12, 13] and
patient specific normal variants detected in PMBCs.
After filtering (described above), the resulting cfDNA
somatic mutations were annotated using the COSMIC
database (https://cancer.sanger.ac.uk/cosmic) for com-
parison with previously reported variants.
Results
CC targeted NGS panel
Generally, liquid biopsies accompanying genomic ana-
lysis alone cannot identify all the features of the primary
tumor. However, genetic alterations occurring in cancer
patients must reflect cancer type specific mutations.
Using our CC-targeted NGS panel, we first tried to de-
tect any CC specific genetic variation in the patients.
Then we sought to check the general mutation patterns
of usual oncogenes, such as PIK3CA or TP53.
Based on TCGA database, we designed NGS CC-panel
(Table 1) consists of 24 genes that are known to occur
in gynecologic cancer at a high frequency. It contains
67% of genes that have been previously reported as sig-
nificantly mutated in many cancers (SMGs - PIK3CA,
EP300, FBXW7, HLA-B, PTEN, NFE2L2, ARID1A, KRAS,
and MAPK [14]). This panel also covers 55% of the top
20, and 80% of the top ten genes detected in CC-related
tumor tissue, according to the COSMIC data. The in-
cluded genes are PIK3CA, KRAS, TP53, PTEN, KMT2C,
FBXW7, KMT2D, EP300, ARID1A, FAT1, and ZFHX3.
The other genes in our panel are related to tumor sup-
pressor activity [15–17].
Evaluation of panel through reference materials
We verified the NGS panel with standard materials to
determine its sensitivity. The standard material (Horizon
Discovery, Cambridge, UK) contains mutations in PIK3-
CA(E545K) and KRAS(G12D) genes. For accuracy, the
sequencing was performed under the same conditions as
the patient samples (10 ng input giving 1000-fold cover-
age). As a result of using 5% Multiplex I cfDNA Reference
Standard, 6.3% variation was detected. Subsequently, 1.3
and 0.13% of allele frequency were identified under the
utilization of 1 and 0.1% of standard material (Fig. 1). In
addition, the average variations for PIKC3A and KRAS
were 1.33 and 1.6%, respectively, based on the verification
using 1% standard material. The allele frequencies of
PIK3CA and KRAS were 0.27 and 0.4%, respectively. All
samples were evaluated in triplicate, and the detection of
standards confirmed that our panel was sensitive enough
to detect 0.1% of genetic variation. To verify the sensitivity
and specificity of this panel, the gene mutations were
identified by digital droplet PCR, which indicated that the
sensitivity for the PIK3CA gene was 88.9% and specificity
was 100%. The result of the ddPCR also confirmed 100%
sensitivity and specificity in the detection of the KRAS
gene (Table 2).
Characteristics of patients
Twenty-four patients with CC were enrolled in this
study. The criteria for enrollment was not case-
controlled; therefore, patients were not specifically
classified by cancer stage or histology, which could
have introduced bias. The clinical and histopatho-
logical characteristics of these patients are summarized
in Table 3. Blood samples were collected from the pa-
tients approximately 1 week prior to primary treat-
ment. Genetic alteration was monitored in four
patients who agreed to provide blood during the treat-
ment, and their blood samples were drawn three times
for the prognosis prediction. The median age in our
cohort was 61 years and 25% (n = 6) of the patients had
disease at stage I, followed by stage II (n = 11, 46%),
stage III (n = 3, 13%), and stage IV (n = 4, 17%) disease.
Histology analysis revealed that cases varied from
adenocarcinoma to invasive CC, and squamous cell
carcinoma was the most common (79%). The stages of
CC were diagnosed using imaging-based methods
(computed tomography and magnetic resonance imaging).
Most of the patients were treated with cisplatin-based
chemotherapy and radiation therapy, and the patients with
small cell neuroendocrine carcinoma were treated with
combination of cisplatin, paclitaxel, and bevacizumab. The
radiation therapy regime was mainly administered to the
pelvic site with 54Gy/30fx followed by ICR (Intracavity
radation) 24Gy/6fx.
Table 1 Gene list in customized CC panel
ARID1A ATM BCOR CHD4 CTCF
CTNNB1 EP300 FAT1 FAT4 FBXW7
FGFR2 KMT2C KMT2D KRAS NSD1
OR14K1 PIK3CA PIK3R1 POLE PTEN
RNF213 TP53 TRRAP ZFHX3
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Genomic alterations in CC patients
The initial study was conducted by screening for overall
genetic variation in patients with CC using our NGS
panel. To explore the profiles of molecular variants, we
analyzed cfDNA and PBMC that were extracted from
the blood of 24 CC patients.
Twenty-four CC patients were sorted by different can-
cer stages and histology features (Fig. 2a and Suppleme-
natary Table 1). All patients with stages III and IV had
the homogenous histology type as squamous cell carcin-
oma. Three patients (among the six patients with stage I
disease) showed the same histology. Among the 24 genes
in the list, alterations were found in 18 genes (75%) and
no mutations were found in the remaining six genes
(BCOR, CTNNB1, FGFR2, OR14K1, POLE, and KRAS).
Genetic mutations in ZFHX3, KMT2C/D, and NDS1
were detected in 20 (83%), 19 (79%), and 16 (67%)
women with CC, respectively (Fig. 2b). These genes have
been reported as tumor suppressors and are prevalent in
other cancer-related diseases [18–23]. According to the
data published by TCGA, PIK3CA (26%), EP300 (11%),
FXBW7 (11%), and PTEN (8%) are the common genetic
variants in CC [14]. However, our analysis showed that
alterations within these genes occurred in 12.5, 12.5, 4,
and 8% of the cases, respectively. Out of all the variant
types, the missense mutations (24%) accounted for the
largest number of variant types. Mutation patterns with
two or more mutation types (such as missense and
frameshift) were found in 15 patients. Frameshift inser-
tions and deletions were found in only five patients.
Overall, at least three genetic variants were found in all
patients, with an average of 9 mutations per patient
Fig. 1 Verification with standard material. Based on comparisons using standard substances, NGS analysis confirmed the allele frequency of
PIK3CA(E545K) and KRAS(G12D) with 1% of accuracy
Table 2 Verification of NGS panel using ddPCR as a gold
standard
Positive Negative Total Sensitivity Specificity
PIK3CA(E545K)
Positive 8 1 9 88.9% 100%
Negative 0 3 3
Total 8 4 12
KRAS(G12D)
Positive 9 0 9 100% 100%
Negative 0 3 3
Total 9 3 12
Table 3 Patient characteristics
Entire cohort 24
Histology
Squamous cell carcinoma 19 (79%)
Endocervical adenocarcinoma 2 (8%)
Small cell neuroendocrine carcinoma 1 (4%)
Low-grade squamous intraepithelial neoplasia 1 (4%)
Invasive cervical cancer 1 (4%)
Pathogenic stage
Stage I 6 (25%)
Stage II 11 (46%)
Stage III 3 (13%)
Stage IV 4 (17%)
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(Fig. 2c). The largest number of mutations was 22
variants in one patient. The total number of distinct
mutations was 217 across all patients. After analyzing
all variants of each gene, the most commonly de-
tected variations were located in KMT2D [23],
followed by the KMT2C [13], FAT4 [10], RNF213 [9],
and ZFHX3 [7] variants (Fig. 2d). Most mutations in
cancer suppressor genes were evenly detected across
all stages of cancer, whereas cancer driver gene vari-
ants were found mainly in the early stages of cancer
(stage I and II).
Variant allele frequency for patient monitoring
Among the 24 patients, 4 patients who agreed to moni-
tor were selected. All assigned patients had been diag-
nosed with CC and showed the same general squamous
cell carcinoma histology. The chemotherapy regimens
were CDDP #6 (cisplatin) and radiotherapy was operated
on pelvis with 54Gy/30fx followed by ICR 24Gy/6fx.
Patient 1 was 74 years old and was confirmed to have
squamous cell carcinoma (stage IV) by surgical pathological
examination. The follow-up period was approximately
19 months. The CC panel analysis revealed a total of
four gene mutations (Fig. 3). In addition to KMT2C
and ZFHX3 mutations found in most patients, PIK3CA
and RNF213 mutations were also detected, and RNF213
mutations changed over 18 months of the examination.
Initial test findings revealed that the uterine cervix had
an intense increment in mass and was approximately 5 cm
in size stained with fluorodeoxyglucose (FDG) and may
have been invaded into the bladder posterior wall. The pa-
tient was treated with CDDP for approximately 2.5months.
After undergoing chemotherapy (P2), a therapeutic effect
was confirmed (partial response; PR). The KMT2C and
PIKC3CA mutations, which were elevated in number in the
early stages of chemotherapy, declined over time. By the
time of the third examination, no PIK3CA and RNF213
mutations were detected. The score for the FATHMM
(http://fathmm.biocompute.org.uk) pathological prediction
is 0.98 for KMT2C and 0.96 for PIK3CA, respectively. The
third examination showed no residues from previous tumor
observation (complete response; CR).
Fig. 2 Somatic alterations in CC. a. Stages and the type of CC histology are represented. b. The Genetic variation panel lists the patient-specific
variations, as well as the sequence of these variations. c. Dot plot indicates the number of variants in CC patients. d. Gray bar graphs show
information for all gene variants, and purple bar graphs show the number of amplicons of gene variants detected in all patients
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Patient 2 was 56 years old and was confirmed to have
squamous cell carcinoma (stage II) by surgical patho-
logical examination. The follow-up period was approxi-
mately 19 months. The patient did not undergo any
further surgery, and the imaging findings revealed FDG-
avid malignancy in the uterine cervix with extension into
the uterine body and fundus. A total of three genetic
mutations were found, which tended to decrease the al-
lele frequencies overall with initial chemotherapy (Fig. 4).
The variation of allele frequency in RNF213, which did
not appear in the first and second examinations, until it
was found at a 3.7% AF during the third examination.
The mutation of KMT2D gene, which is considered as
pathologic (0.84) according to the FATHMM prediction,
was detected in the first screening but disappeared in
the second screening and then reappeared in the third
screening. The genetic variation of ZFHX3 was found to
decrease in the early phase of chemotherapy (2.1%), but
increased over time (7.2%). At the third clinical examin-
ation, a mass distinct from the cervix was detected, and
a slight thickening across the endometrium was also de-
tected; otherwise, no measurable enlarged lymph nodes
or fluid collections were observed around the lesion. As
a result, although the CC size did not increase signifi-
cantly, this patient was diagnosed with partial response
to chemotherapy, due to other factors around cervix le-
sion site.
Patient 3 was 48 years old and had squamous cell car-
cinoma type CC (stage II) which tended to be kerati-
nized. The patient had mutations in two genes (KMT2D
and ZFHX3); the KMT2D mutation, which is considered
as pathogenic (score 0.84), disappeared by the second
and third screening (Fig. 5). The initial screening showed
localized metastasis to the lymph node (LN) region of
the uterine cervix and multiple myomas in the uterus.
The treatment of this patient involved approximately 2
months of chemotherapy. Ten months later, the third
examination was performed. Examination revealed no le-
sion sites in the uterine cervix. The LN of approximately
1.3 cm was still visible but was decreased in size. Add-
itionally, leiomyoma of less than 4 cm was observed in
the uterus. However, several uterine leiomyoma and
endometrial polyps were observed (PR).
Patient 4 was 51 years old and had stage III cancer.
The patient was followed up for approximately 13
months. The patient’ positron emission spectroscopy im-
ages showed an FDG-avid mass (SUVmax = 22.33) of a
metabolic size of approximately 5 × 2.5 cm in the uterine
cervix in the abdomen and pelvis. The metabolic length
was approximately 5.5 cm, extending into the vagina and
abutting the bladder base. Both external iliac LNs were
up to 8 mm in diameter and showed FDG uptake. Other
internal iliac LNs appeared to be small in size and did
not show FDG uptake. In this patient, three major gene
Fig. 3 Patient specific features of tumor suppressor gene mutation. PR: partial response. CR: complete response. P1: Period 1, P2: Period 2, P3: Period 3
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Fig. 5 Patient specific features of tumor suppressor gene mutation
Fig. 4 Patient specific features of tumor suppressor gene mutation
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mutations (KMT2D, NSD1 and RNF213) were found
(Fig. 6). After treatment, the two of the three genetic
variants disappeared. The RNF213 gene mutation was
not observed in the first screening, whereas its AF was
found in the second and third screenings. After the third
examination, lesions observed in the cervix and vagina
anterior portions were not visible. There was no change
in the sub centimeter-sized myomas in the uterine fun-
dus. No significantly enlarged LN was observed in the
pelvic cavity, and no abnormal fluid collection was ob-
served. There were no abnormal findings in the metasta-
ses, urinary bladder, and rectum in the pelvic bone. In
conclusion, a complete response was confirmed based
on the difficulty in detecting the lesion site.
Discussion
In the present study, we analyzed cfDNA from patients
with CC by NGS using a customized panel of 24 cancer-
related genes using the Ion Torrent system. The study
was conducted to identify cfDNA mutations and explore
their effectiveness in diagnosing and monitoring CC.
There were three key challenges faced during this study.
(i) All 24 subjects provided cancer-positive samples,
however, we did not have non-patients samples to com-
pare with. For a better understanding of the cancer-
positive DNAs, samples from healthy donors must be
included in cfDNA library preparation and sequencing,
and cut-off values must also be validated more robustly
for variant calling. (ii) In the analysis of assay specificity,
there was excessive noise in variant calling. According to
TCGA, there was an average of 4 mutations per Mbp.
Although we minimized the technical errors and germ-
line variants, there were approximately five mutations in
52 Mbp. Various data must be included to demonstrate
the specificity of somatic variant calling. These data may
include a list of specific variant locations and nucleotide
changes across all samples. Other than established hot-
spot mutations, repeated variants across multiple sam-
ples may indicate technical errors. (iii), The detection
sensitivity was limited. The levels of mutations in
PIK3CA, KRAS, and TP53, the most relevant mutated
genes in CC, were lower than expected. Because of the
small positive cohort group (24 CC-positive patients),
statistical analysis was difficult. Technical evaluation
must be performed to further evaluate the assay
sensitivity.
Recent studies have shown that the role of KMT2C/D
gene is generally known to perform enhancer regulation
by deposition of H3K4me1 in normal cells [24, 25] and a
transcription regulator in cancer [26, 27]. Likewise the
KMT2C/D gene, which may play an important role in
cancer, is reported to have a frequency of up to 89%
Fig. 6 Patient specific features of tumor suppressor gene mutation
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somatic mutation in esophageal squamous cell carcinoma
(ESCC), medulloblastoma, follicular lymphoma, and dif-
fuse large B-cell lymphoma patients [28]. More intri-
guingly, G. Paolo et al. showed that the frequency of
KMT2C/D gene mutation was also notable in patients
with histology of Cutaneous squamous cell carcinoma
(SCC), head and neck SCC, lung SCC, esophageal SCC,
and cervical SCC [29]. In similar to these studies, our re-
sults indicate that mutation rates of ZFHX3, KMT2C,
KMT2D, NSD1, and RNF213 genes have existed at a high
frequency in CC patients in despite of the characteristics
of these genetic mutations that have not been clearly iden-
tified in CC patients. The reason is that 79% of histologic
subtype of CC in our cohort is consisted of squamous cell
carcinoma (Table 1). Therefore, our findings on these gen-
etic variations may be applicable to future studies of the
molecular mechanism of cervical cancer.
In addition, RNF213 mutation, which was employed as
a monitoring marker for CC patients in our study, is
currently little known about its function and role in can-
cer. RNF213 is primarily known as E3 ubiquitin-protein
ligase involved in angiogenesis and non-canonical signal
pathway in vascular development. A preceding study is
mainly focused on Moyamoya disease, and a cerebrovas-
cular disease characterized by progressive bilateral sten-
osis of internal carotid arteries [30]. Therefore, the role
of RNF213 in cervical cancer is required for further in-
vestigation and must be validated as a prognostic factor
to measure clinical outcomes during cervical cancer
treatment.
We report several important aspects regarding the
promising application of cfDNA for early diagnosis and
monitoring of CC: (i) Gene mutation can serve as a
prognostic biomarker for detecting CC by the profiling
of the tumor suppressor and cancer driver genes. (ii)
Mutations in tumor suppressor genes are prevalent in all
stages of CC, and (iii) Chemotherapy and radiotherapy
affect the allele frequency, which can be utilized for
monitoring cancer. We also report the comprehensive
mutation profile of CC samples. Notably, frequently mu-
tated genes, such as TP53 or PIK3CA in CC, were not
predominantly identified in 24 Korean women. Interest-
ingly, during the course of treatment of CC, we discov-
ered that continuous observation of Tumor suppressor
gene mutations could be employed to reveal the appro-
priate treatment modalities in patients. This approach of
using liquid biopsy to detect the mutation pattern can
be used in clinical practice. Although specific anticancer
drugs for CC treatment have not yet been approved by
the Food and Drug Administration, drugs prescribed for
other carcinomas or radiation therapy can be used. Add-
itionally, NGS technology, which can be explicitly used
for the diagnosis of CC, needs to have a more accurate
clinical specificity by minimizing false-positive diagnosis.
Conclusion
CC is the cause of malignancy-related death among
women. For the clinically usage in clinicians and patients
parts, we developed the NGS CC panel. Through NGS
analysis with blood samples in Korean women, the gen-
etic variations in CC were found that are related to the
genetic alteration result of TCGA and COSMIC data.
Although we have some technical tasks to improve, we
showed the advanced step of CC diagnosis with the NGS
technology with blood. Our multifaceted approach to
assessing genetic variations can be used for the diagno-
sis, monitoring, and further treatment of CC.
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